Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab
This is an open label Phase II Trial that using the investigational anti-cancer agent, Pazopanib to see whether non-squamous non-small cell lung cancer will respond to its use by decreasing the size of the tumor or stopping its growth.
Checked against the public recordLast updated Mar 7, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Interventions being studied
- Drug: Pazopanib
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Age 18 or older * Stage IIIB (with malignant pleural or pericardial effusion or supraclavicular lymph node involvement) or stage IV NSCLC * Evidence of progression while on bevacizumab * Patients treated for CNS metastases who are asymptomatic with no requirement for steroids for 2 weeks prior to first dose of study drug Exclusion Criteria: * Prior malignancy * Clinically significant gastrointestinal abnormalities * Presence of uncontrolled infection or nonhealing wound, fracture, or ulcer * History of cardiovascular conditions within the past 6 months
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- North Carolina Cancer Hospital at U of North Carolina at CHChapel Hill, North Carolina
- University of Pittsburgh Medical CenterPittsburgh, Pennsylvania
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 7, 2017. Always confirm current availability with the study team.